Photo: Gil C / Shutterstock.com
Kite Pharma, a biotech company, has entered into a licensing agreement with the US’s National Institute of Health (NIH) that will give it the IP rights to T-cell therapies developed to treat cancer.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Kite Pharma, NCI, NIH, T-cell therapies, antigen NY-ESO-1
